1. In Vivo
  2. >>Leadership
  3. >>Rising Leaders

Next-Gen ADCs: Araris CEO Highlights Potential In Linker Technology

 
• By Janelle Hart

In Vivo sat down with 2023 Rising Leader Philipp Spycher, CEO of Araris Biotech, to discuss trends in antibody-drug conjugate R&D, and how Araris hopes to disrupt today’s chemotherapy treatment paradigm with novel linker technology.

Antibody-drug conjugates
• Source: Shutterstock

Rising Leaders Home

The antibody-drug conjugate (ADC) space is exploding, and Araris Biotech AG is on the front line with novel linker...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rising Leaders

More from Leadership